| Property | Value |
|---|
|
?:abstract
|
-
Asthma and Chronic Obstructive Pulmonary Disease (COPD) patients are considered at increased risk of dying from COVID-19 and were therefore subject to UK government shielding advice. While this may have protected against respiratory viruses; adverse effects, including reduced physical activity, social isolation, and increasing anxiety have been recognised consequences [3]. Airways disease management is multidisciplinary and there may also be pervasive deleterious effects due to suspension of clinical services including out-patient clinics, smoking cessation support, and pulmonary rehabilitation (PR) [4]. A recent national survey found that up to 23% of patients with lung conditions have experienced worsening symptoms during the pandemic [5].
|
|
is
?:annotates
of
|
|
|
?:creator
|
|
|
?:doi
|
|
|
?:doi
|
-
10.1183/23120541.00822-2020
|
|
?:journal
|
|
|
?:license
|
|
|
?:pdf_json_files
|
-
document_parses/pdf_json/7dc6943ca46a1093ece2594002d61efdf9f51f28.json
|
|
?:pmcid
|
|
|
?:pmid
|
|
|
?:pmid
|
|
|
?:publication_isRelatedTo_Disease
|
|
|
?:sha_id
|
|
|
?:source
|
|
|
?:title
|
-
Impact of COVID-19 on COPD and Asthma admissions and the pandemic from a patient\'s perspective
|
|
?:type
|
|
|
?:year
|
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}